Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Biomarker Study of the Effects of Dexpramipexole on Eosinophils in Subjects With Eosinophilic Asthma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexpramipexole (Primary)
Indications Asthma
Focus Proof of concept; Therapeutic Use
Acronyms EXHALE; EXHALE-1
Sponsors Knopp Biosciences

Most Recent Events

03 Aug 2023 Results published in the Areteia Therapeutics Media Release.
03 Jun 2023 Results published in the Journal of Allergy and Clinical Immunology.
28 Feb 2022 Results of post hoc analysis presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma and Immunology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com